2. Search Result
Search Result
Results for "

atopic

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145551
    Atinvicitinib

    		Others Inflammation/Immunology
    Atinvicitinib is a kind of pyrazole compound. Atinvicitinib has the potential for the research of atopic dermatitis (extracted from patent WO2021123094A1) .
    Atinvicitinib
  • HY-P99301
    Lokivetmab

    Anti-Canine IL31 Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology
    Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
    Lokivetmab
  • HY-131707
    LEO 39652

    		Phosphodiesterase (PDE) Inflammation/Immunology
    LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) .
    LEO 39652
  • HY-P99053
    Tralokinumab

    		Interleukin Related Inflammation/Immunology
    Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .
    Tralokinumab
  • HY-P99162
    Nemolizumab

    CIM331

    		 Interleukin Related Inflammation/Immunology
    Nemolizumab (CIM331) is a humanized antihuman interleukin-31 receptor A monoclonal antibody that inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD) .
    Nemolizumab
  • HY-B1616
    Clobetasone butyrate
    1 Publications Verification

    		 Glucocorticoid Receptor Inflammation/Immunology
    Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
    Clobetasone butyrate
  • HY-148074
    Zelnecirnon

    RPT193

    		 CCR Inflammation/Immunology
    Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research .
    Zelnecirnon
  • HY-109085
    Difamilast
    1 Publications Verification

    OPA-15406

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) .
    Difamilast
  • HY-100009
    Ufenamate

    Flufenamic acid butyl ester; Butyl flufenamate

    		 Others Inflammation/Immunology
    Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory agent. Ufenamate can be used for the research of skin diseases, such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliaria and atopic dermatitis .
    Ufenamate
  • HY-P99519
    Vixarelimab

    KPL-716

    		 Interleukin Related Inflammation/Immunology
    Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
    Vixarelimab
  • HY-13723A
    Pimecrolimus hydrate

    SDZ-ASM 981 hydrate

    		 Phosphatase Inflammation/Immunology
    Pimecrolimus hydrate (SDZ-ASM 981 hydrate) is a potent, nonsteroid and orally active calcineurin inhibitor. Pimecrolimus hydrate shows anti-inflammatory activity. Pimecrolimus hydrate has the potential for the research of atopic dermatitis and oral erosive lichen planus .
    Pimecrolimus hydrate
  • HY-145351
    BAY 1003803

    		Glucocorticoid Receptor Inflammation/Immunology
    BAY 1003803 is a glucocorticoid receptor agonist for the topical research of psoriasis or severe atopic dermatitis.
    BAY 1003803
  • HY-B1365
    Prednicarbate

    Prednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis .
    Prednicarbate
  • HY-18706
    trans-Tranilast

    trans-MK-341; trans-SB 252218

    		 Angiotensin Receptor Inflammation/Immunology Endocrinology
    trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.
    trans-Tranilast
  • HY-106714
    Clocortolone pivalate

    		Drug Metabolite Inflammation/Immunology
    Clocortolone pivalate is a synthetic glucocorticoid corticosteroid and corticosteroid ester. Clocortolone pivalate is indicated for seborrheic dermatitis, contact dermatitis, atopic dermatitis and psoriasis .
    Clocortolone pivalate
  • HY-N0184A
    Dipotassium glycyrrhizinate
    Maximum Cited Publications
    22 Publications Verification

    Glycyrrhizic acid dipotassium; Dipotassium glycyrrhizate

    		 Virus Protease Metabolic Disease Inflammation/Immunology
    Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity .
    Dipotassium glycyrrhizinate
  • HY-P99018
    Etokimab

    Antibody ANB 020

    		 Interleukin Related Cancer
    Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis .
    Etokimab
  • HY-156621
    Lepzacitinib

    		JAK Inflammation/Immunology
    Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .
    Lepzacitinib
  • HY-A0150
    Alclometasone

    7a-​Chloro-​16a-​methyl prednisolone
    Alclometasone (7a-Chloro-16a-methyl prednisolone) is a glucocorticoid and inhibits the release of pro-inflammatory mediators from leukocytes. Alclometasone can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis, eczema, psoriasis and allergic dermatitis .
    Alclometasone
  • HY-P9926
    Dupilumab
    1 Publications Verification

    REGN-668; SAR-231893

    		 Interleukin Related Inflammation/Immunology Cancer
    Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
    Dupilumab
  • HY-134772
    AS1810722

    		STAT Cytochrome P450 Inflammation/Immunology
    AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research .
    AS1810722
  • HY-B0725A
    Doxepin

    Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress .
    Doxepin
  • HY-B0195
    Tranilast
    5+ Cited Publications

    MK-341; SB 252218

    		 Angiotensin Receptor Prostaglandin Receptor Inflammation/Immunology Endocrinology Cancer
    Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects . Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells .
    Tranilast
  • HY-B0195A
    Tranilast sodium

    MK-341 sodium; SB 252218 sodium

    		 Prostaglandin Receptor Angiotensin Receptor Inflammation/Immunology Endocrinology
    Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects . Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells .
    Tranilast sodium
  • HY-P99673
    Itepekimab

    REGN-3500; SAR-440340

    		 Interleukin Related NF-κB Inflammation/Immunology
    Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
    Itepekimab
  • HY-B0636
    Triamcinolone acetonide
    3 Publications Verification

    		 Glucocorticoid Receptor FGFR Inflammation/Immunology Endocrinology Cancer
    Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis .
    Triamcinolone acetonide
  • HY-N4042
    Hirsutenone

    		PI3K ERK Inflammation/Immunology Cancer
    Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity .
    Hirsutenone
  • HY-156622
    Leramistat

    HMC-C-01-A; MBS2320

    		 Mitochondrial Metabolism Cancer
    Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM). Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease .
    Leramistat
  • HY-103018
    Gusacitinib
    1 Publications Verification

    ASN-002

    		 JAK Syk Inflammation/Immunology Cancer
    Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib
  • HY-103018A
    Gusacitinib hydrochloride

    ASN-002 hydrochloride

    		 JAK Syk Inflammation/Immunology Cancer
    Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib hydrochloride
  • HY-162004
    NF-κB-IN-14

    		NF-κB Toll-like Receptor (TLR) Inflammation/Immunology
    NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .
    NF-κB-IN-14
  • HY-A0015
    Bepotastine besilate
    1 Publications Verification

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
    Bepotastine besilate
  • HY-I0021
    Bepotastine
    1 Publications Verification

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Bepotastine is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
    Bepotastine
  • HY-I0021A
    Bepotastine tosylate

    		Histamine Receptor Inflammation/Immunology Endocrinology
    Bepotastine tosylate is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine tosylate can suppress the expression of nerve growth factor (NGF). Bepotastine tosylate can be used in studies of allergic rhinitis, allergic conjunctivitis and urticaria/pruritus .
    Bepotastine tosylate
  • HY-A0015A
    (Rac)-Bepotastine besilate

    		Others Inflammation/Immunology Endocrinology
    (Rac)-Bepotastine (besilate) is the isomer of Bepotastine (besilate) (HY-A0015), and can be used as an experimental control. Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
    (Rac)-Bepotastine besilate
  • HY-B0725
    Doxepin Hydrochloride
    4 Publications Verification

    		 Histamine Receptor Cytochrome P450 Neurological Disease Cancer
    Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .
    . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system .
    . Doxepin has also been proposed as a protective factor against oxidative stress .
    .
    Doxepin Hydrochloride
  • HY-B0725R
    Doxepin Hydrochloride (Standard)

    		Histamine Receptor Cytochrome P450 Neurological Disease Cancer
    Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .
    . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system .
    . Doxepin has also been proposed as a protective factor against oxidative stress .
    .
    Doxepin Hydrochloride (Standard)
  • HY-13723
    Pimecrolimus
    2 Publications Verification

    SDZ-ASM 981

    		 Phosphatase Inflammation/Immunology
    Pimecrolimus (SDZ-ASM 981) is a potent, nonsteroid and orally active calcineurin inhibitor with a Ki of 117 nM. Pimecrolimus shows anti-inflammatory activity .
    Pimecrolimus

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: